Johnson Matthey to sell health business for £325m
It will retain a 30 per cent stake in the division, which develops and manufactures specialist pharmaceutical ingredients for pharma and biotechnology customers.
Source: thisismoney.co.uk
Stay updated with breaking news from Robert Macleod. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
It will retain a 30 per cent stake in the division, which develops and manufactures specialist pharmaceutical ingredients for pharma and biotechnology customers.
It will retain a 30 per cent stake in the division, which creates complex and specialist pharmaceutical ingredients for pharma and biotechnology customers.
UPDATE: Johnson Matthey sells Health unit after Battery Materials exit | Financial News
Investegate announcements from Johnson Matthey PLC, Director/PDMR Shareholding